Roche Holding AG (GB:0QOK)
LSE:0QOK
0QOK Stock Chart & Stats
CHF312.14
CHF8.64(3.34%)
At close: 4:00 PM EST
CHF312.14
CHF8.64(3.34%)
Day’s Range― - ―
52-Week RangeCHF221.30 - CHF377.00
Previous CloseN/A
Volume341.09K
Average Volume (3M)433.97K
Market Cap
CHF253.14B
Enterprise ValueCHF278.15B
Total Cash (Recent Filing)CHF15.48B
Total Debt (Recent Filing)CHF31.64B
Price to Earnings (P/E)20.3
Beta0.86
Next Earnings
Jul 23, 2026EPS Estimate
10.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.38
Shares Outstanding702,562,700
10 Day Avg. Volume520,275
30 Day Avg. Volume433,969
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF350.21Price Target Upside12.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)20.24
Revenue Forecast (FY)CHF62.90B
Bulls Say, Bears Say
Bulls Say
Adjuvant Breast Cancer Market OpportunityGiredestrant's improved tolerability and potential to permit switching from aromatase inhibitor therapy could expand the eligible adjuvant patient pool and attract patients who avoid more toxic combination regimens.
Clinical Efficacy In Relapsing Multiple SclerosisFENhance trials reported substantial reductions in relapses and brain lesions versus the comparator, indicating fenebrutinib could deliver a meaningful efficacy advantage in relapsing multiple sclerosis.
Diagnostics Technology And DiversificationNew sequencing, sensor, and automated mass spectrometry platforms position Diagnostics to capture incremental share through faster and more flexible testing, continuous glucose monitoring integration, and broad laboratory workflows, helping offset pharmaceutical patent pressures.
Bears Say
Analyst Caution From Prior Trial OutcomesLegacy high‑risk trial failures and unresolved uncertainties around endocrine sensitivity have led to analyst caution, which could sustain downside pressure if upcoming data do not reduce perceived trial risk.
Regulatory And Evidentiary HurdlesRemaining questions on statistical significance and the need for definitive randomized studies for giredestrant combinations create regulatory and payer hurdles that could delay widespread adoption.
Safety Signals In Clinical TrialsAn imbalance in fatal cases and liver toxicity signals in fenebrutinib studies raises material safety concerns that could limit regulatory clearance and clinician confidence.
Roche Holding AG News
0QOK FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest share price was CHF221.30 and its highest was CHF377.00 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is CHF253.14B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jul 23, 2026 which is in 104 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jan 29, 2026. The company reported CHF8.375 earnings per share for the quarter, missing the consensus estimate of CHF8.515 by -CHF0.14.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG does not currently pay dividends.
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 10.76.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of CHF8.375 in its last earnings report, missing expectations of CHF8.515. Following the earnings report the stock price went up 1.883%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in GB:0QOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.
0QOK Company Deck
0QOK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong operational execution: group sales +7% (Pharma +9%), core operating profit +13% and meaningful pipeline momentum with multiple positive Phase III readouts, approvals, a record 10 NMEs entering Phase III and launches (AXELIOS sequencing, mass spec, dengue test). Roche also secured a major U.S. government agreement and committed large U.S. investments. Material headwinds were acknowledged — notably Diagnostics headwinds from China pricing reforms (CHF 579m impact), FX and cash-flow/working capital pressures, higher taxes reducing EPS momentum, LOE effects (~CHF 700m) and safety/regulatory scrutiny (fenebrutinib liver signal). Management provided 2026 guidance (mid-single-digit sales growth, high single-digit Core EPS growth) and expects Diagnostics headwinds to diminish in 2026 and largely disappear by 2027. Overall, the positives from sales, margin expansion, prolific pipeline and strategic investments substantially outweighed the operational and market challenges discussed.View all GB:0QOK earnings summaries0QOK Stock 12 Month Forecast
Average Price Target
CHF350.21
▲(12.20% Upside)
Technical Analysis
Options Prices
Currently, No data available
---